Cilostazol | 73963-72-1

Cilostazol Properties

Melting point	159-160°C
Boiling point	499.57°C (rough estimate)
Density	1.1832 (rough estimate)
refractive index	1.7600 (estimate)
storage temp.	Inert atmosphere,Room Temperature
solubility	DMSO: 18 mg/mL, soluble
form	solid
pka	14.22±0.20(Predicted)
color	off-white
λmax	257nm(MeOH)(lit.)
Merck	14,2277
Stability	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months
InChIKey	RRGUKTPIGVIEKM-UHFFFAOYSA-N

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS08
Signal word	Warning
Hazard statements	H361d
Precautionary statements	P201-P202-P280-P308+P313-P405-P501
Hazard Codes	Xi
WGK Germany	2
RTECS	VC8277500
HS Code	29339900
Toxicity	LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura)

Cilostazol price More Price(5)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich(India)	PHR1503	Cilostazol Pharmaceutical Secondary Standard; Certified Reference Material	73963-72-1	1G	₹15025.1	2022-06-14	Buy
Sigma-Aldrich(India)	C0737	Cilostazol ≥98% (HPLC), powder	73963-72-1	10MG	₹20177.8	2022-06-14	Buy
Sigma-Aldrich(India)	C0737	Cilostazol ≥98% (HPLC), powder	73963-72-1	50MG	₹80646.25	2022-06-14	Buy
TCI Chemicals (India)	C2587	Cilostazol	73963-72-1	1G	₹7500	2022-05-26	Buy
TCI Chemicals (India)	C2587	Cilostazol	73963-72-1	5G	₹8000	2022-05-26	Buy

Product number	Packaging	Price	Buy
PHR1503	1G	₹15025.1	Buy
C0737	10MG	₹20177.8	Buy
C0737	50MG	₹80646.25	Buy
C2587	1G	₹7500	Buy
C2587	5G	₹8000	Buy

Cilostazol Chemical Properties,Uses,Production

Description

Cilostazol is a platelet aggregation inhibitor with cerebral vasodilating activity, indicated for use in stroke and myocardial infarction. In patients with cerebral thrombosis, transient ischemia and cerebral arteriosclerosis, cilostazol significantly inhibits ADP-, collagenand epinephrine-induced platelet aggregation. Side effects include headache and tachycardia.

Chemical Properties

Colourless Needles

Uses

A potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake. Has antimitogeni, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo

Definition

ChEBI: A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substiuted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group.

General Description

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Biological Activity

Potent phosphodiesterase III A (PDE3A) inhibitor (IC 50 = 0.2 μ M) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo . Also affects lipid levels in vivo .

Mechanism of action

Cilostazol exhibits greater selectivity than dipyridamole as an inhibitor of PDE3A. The drug does not affect the other PDEs (PDEs 1, 2, or 4). Cilostazol reversibly inhibit platelet aggregation induced by a number of stimuli, such as thrombin, ADP, collagen, or stress from exercise. Additionally, cilostazol inhibits adenosine uptake, leading to increased activity of adenosine at A1 and A2 receptors.

Clinical Use

Cilostazol, a quinolinone derivative, is a potent orally active antiplatelet drug approved for the treatment of intermittent claudication (a peripheral artery disease resulting from blockage of blood vessels in the limbs).

Metabolism

Cilostazol is rapidly absorbed after oral administration, particularly with a high-fat meal, which greatly increases its bioavailability to approximately 90%. It is extensively metabolized in the liver by various cytochromes. The most important cytochromes appear to be CYP3A4 and, to lesser extent, by CYP2C19, with an elimination half-life of approximately 11 to 13 hours. Among the various metabolites produced (11 metabolites are known), the two major metabolites are 3,4-dehydrocilostazol and 4′-trans-hydroxycliostazol. These two metabolites are pharmacologically active. Studies indicate that the concomitant administration of cilostazol with CYP3A inhibitors can greatly increase cilostazol blood concentrations, and a dose reduction may be required. Similar results are seen when CYP2C19 is inhibited, leading to decreased formation of 4-trans-hydroxycliostazol and significant increases in cilostazol and 3,4-dehydrocilostazol.

Cilostazol Preparation Products And Raw materials

Raw materials

Pentanamide Sodium sulfate Tetrazole 3,4-DIHYDROQUINOLIN-2(1H)-ONE Water

Phosphorus pentachloride

chevron_left

1of2

chevron_right

Preparation Products

Cilostazol Related Compound C (50 mg) (1-(4-(5-Cyclohexyl-1H-tetrazol-1-yl)butyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one)

Cilostazol Suppliers

Global( 536)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
Cadila Pharmaceuticals Ltd	+91-7069076657 +91-7069076657	Ahmedabad, India	54	58	Inquiry
SEUTIC	+91-8309787199 +91-8309787199	Hyderabad, India	124	58	Inquiry
KARUNESH REMEDIES	+919998776849	Gujarat, India	18	58	Inquiry
Glenmark Pharmaceuticals Limited	+912240189999	Maharashtra, India	93	58	Inquiry
Hetero Drugs Limited	+91-4023704923 +91-4023704923	Telangana, India	296	58	Inquiry
Ipca Laboratories Ltd	+91-2262105000 +91-2262105000	Maharashtra, India	61	58	Inquiry
Dayaram Pharma Chem	+91-9601766800 +91-9601766800	Gujarat, India	61	58	Inquiry
Afton Pharma	+91-9712000202 +91-9712000202	Gujarat, India	63	58	Inquiry
Fleming Laboratories Ltd	+91-9666407333 +91-9666022445	Hyderabad, India	22	58	Inquiry
Cleargreens Pharmaceutical Private Limited	+91-9879791802 +91-9579898158	Gujarat, India	14	58	Inquiry

Supplier	Advantage
Cadila Pharmaceuticals Ltd	58
SEUTIC	58
KARUNESH REMEDIES	58
Glenmark Pharmaceuticals Limited	58
Hetero Drugs Limited	58
Ipca Laboratories Ltd	58
Dayaram Pharma Chem	58
Afton Pharma	58
Fleming Laboratories Ltd	58
Cleargreens Pharmaceutical Private Limited	58

Cilostazol Spectrum

Cilostazol(73963-72-1)¹HNMR

73963-72-1(Cilostazol)Related Search:

GJXNGCFWGJQETE-UHFFFAOYSA-N Cilostazol Impurity Cilostazol Related Compound C (50 mg) (1-(4-(5-Cyclohexyl-1H-tetrazol-1-yl)butyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one) N-Hexadecyltrimethylammonium chloride Epoprostenol

2-Quinolinol Pentetrazol Dihydromyrcenol 6-HYDROXY-2(1H)-3,4-DIHYDROQUINOLINONE CILOSTAZOL INTERMEDIATE,The intermediate of Cilostazol,Intermediate of Cilostazol 6-Methoxy-3,4-dihydro-1H-quinolin-2-one

5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole (intermediate of cilostazol) 6-[3-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) PROPOXY]-2(1H)-QUINOLINONE 5-AZIDO-VALERIANIC ACID 3-azidopropanoic acid 3,4-Dehydro Cilostazol

4-CIS-HYDROXY CILOSTAZOL 4trans-Hydroxy Cilostazol Cilostazol-d11,CILOSTAZOL METABOLITE

chevron_left

1of4

chevron_right

6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1h)-quinolinone additional name: 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone OPC-13013, Pletal, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one CILOSTAZOL JP 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE(CILOSTAZOL) OPC 13013, OPC 21, Pletaal, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone 6-[4-(1-Cyclohexyl-1H-tetrazol-5-y1)butoxy]-3，4-dihydrcr2(1H)-quinolinone 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolone Cilostazol (200 mg) Cilostazol, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one Cilostazol(Micronized 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)quinoline-2,3(1H,4H)-dione 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro- CILASTAZOL CILOSTAZOL CILOSTAZOLE RETAL OPC 13013 OPC 21 PLETAL PLETAAL 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4-tetrahydro-2-oxoquinolinone Cilostal CILOSTAZOL INTERMEDIATES N-cyclohexyl-5-(4-chlorobutyl)tetrazol CilostazolC20H27N502 6-[4-(1-cyclohexyl -1H-tetrazole -5-sulfuryl )butoxy ]-3,4-dihydro -2(1H)-quinolone THE INTERMEDIATE OF CILOSTAZOL(N-CYCLOHEXYL-5-(4-CHLOROBUTYL)TETRAZOL) 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinon 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinone Cilostazo 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one Cilostazol > Cilostazol Cilostazol Cilostazol RS Cilostazol USP/EP/BP Cilostazol (OPC-13013 CilostazolQ: What is Cilostazol Q: What is the CAS Number of Cilostazol Q: What is the storage condition of Cilostazol Q: What are the applications of Cilostazol Cilostazol (1134153) Cilostazol IP/USP ciloprost impurities Cilostazol, ≥ 98.0% Compound A86 73963-72-1 73693-72-1 76963-72-1 C20H27N5O2 C20H27O2N5 Cell Signaling and Neuroscience Cell Biology BioChemical Cyclic Nucleotide Metabolism G Proteins and Cyclic Nucleotides Phosphodiesterase Inhibitors inhibitor Cardiovascular APIs